AbCellera Biologics Inc vs General Dynamics Corporation — how do they compare? AbCellera Biologics Inc trades at $9.11 (market cap $2.99B), while General Dynamics Corporation trades at $391.11 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 35.5× AbCellera Biologics Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GD | |
|---|---|---|
Market Cap | $2.99B | $106.03B |
Sector | Health | Industrials |
52-Week High | $9.76 | $395.97 |
52-Week Low | $2.78 | $312.53 |
Enterprise Value | $2.58B | $111.17B |
Dividend Yield | — | 1.62% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →